Summary of HR 4299: Protecting Patient Access to Cancer and Complex Therapies Act

Purpose and Intent

The Protecting Patient Access to Cancer and Complex Therapies Act (HR 4299) aims to ensure that patients have continued access to essential cancer treatments and complex therapies. The bill addresses concerns regarding the availability and affordability of these critical healthcare services, particularly in light of recent changes in healthcare policies and insurance coverage.

Key Provisions

While the full text of the bill has not been provided, the following key provisions are anticipated based on the bill's title and legislative intent:

• Patient Access: The bill is expected to include measures that protect patient access to necessary cancer treatments and therapies, potentially by regulating insurance practices that may limit access.

• Insurance Coverage: It may propose changes to insurance coverage requirements, ensuring that patients are not denied coverage for specific cancer treatments deemed medically necessary.

• Cost Transparency: The legislation could introduce provisions aimed at increasing transparency in the costs associated with cancer therapies, helping patients make informed decisions about their treatment options.

• Support for Providers: The bill may also include support mechanisms for healthcare providers to ensure they can offer these therapies without facing undue financial burdens.

Affected Parties

The following groups are likely to be impacted by HR 4299:

• Patients: Individuals diagnosed with cancer or requiring complex therapies will benefit from improved access and potentially reduced costs for treatments.

• Healthcare Providers: Oncologists, hospitals, and clinics that provide cancer care may see changes in reimbursement practices and support for delivering therapies.

• Insurance Companies: The bill may impose new regulations on insurance providers regarding coverage for cancer treatments, which could affect their policies and practices.

Legislative Process and Timeline

• Introduced: The bill was introduced in the House on July 7, 2025.

• Committee Referral: It has been referred to the Committee on Energy and Commerce and the Committee on Ways and Means for consideration. The specific timeline for further action will be determined by the Speaker of the House.

Conclusion

HR 4299 seeks to enhance patient access to vital cancer treatments and complex therapies, addressing significant healthcare challenges faced by patients and providers. As the bill progresses through the legislative process, further details will emerge regarding its specific provisions and potential impacts on the healthcare landscape.